Tourmaline Bio Inc.
(TRML)
undefined
undefined%
At close: undefined
21.81
-0.37%
After-hours Dec 13, 2024, 04:00 PM EST
Company Description
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases.
It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED).
The company was incorporated in 2021 and is based in New York, New York.
Tourmaline Bio Inc.
| Country | United States |
| IPO Date | May 7, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 74 |
| CEO | Dr. Sandeep C. Kulkarni M.D. |
Contact Details
Address: 27 West 24th Street New York, New York United States | |
| Website | https://www.tourmalinebio.com |
Stock Details
| Ticker Symbol | TRML |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001827506 |
| CUSIP Number | n/a |
| ISIN Number | US89157D1054 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sandeep C. Kulkarni M.D. | Co-Founder, Chief Executive Officer & Director |
| Dr. Susan Dana Jones Ph.D. | Chief Technology Officer |
| Ryan Robinson CPA | Chief Financial Officer & Treasurer |
| Dora Rau | Senior Vice President & Head of Quality |
| Dr. Emil M. deGoma M.D. | Senior Vice President of Medical Research |
| Dr. Kevin B. Johnson M.B.A., Ph.D. | Chief Regulatory Officer |
| Dr. Kristine Erickson O.D., Ph.D. | Vice President & TA Head of Ophthalmology, Medical Research |
| Gerhard Hagn Pharm.D. | Senior Vice President and Head of Commercial & Business Development |
| Kimberly Piorkowski | Vice President of People, Culture & Compliance |
| W. Bradford Middlekauff J.D. | Chief Business Officer, General Counsel & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 07, 2024 | S-3 | Filing |
| Nov 07, 2024 | 10-Q | Quarterly Report |